OXiGENE to Report on ZYBRESTAT(TM) Pivotal Trial Progress in Presentation to Investors in Sweden WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 11, 2007--Regulatory News: OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that Richard Chin, M.D., President and CEO, will present a corporate update to investors in Stockholm, Sweden, on December 11, 2007. Included in the presentation will be an update on the progress of OXiGENE's ongoing Phase II/III pivotal registration study of ZYBRESTAT(TM) for anaplastic thyroid cancer (ATC). OXiGENE indicated that it has initiated a total of four clinical trial sites in the United States and India, and anticipates initiating two to three additional sites prior to year-end. Additional regulatory submissions and reviews are in progress to support initiation of further study sites in the United States, Europe, Russia, and Israel beginning in January 2008. Based upon meetings with investigators from approximately 30 sites conducted this fall in India, the United States and Europe, OXiGENE anticipates having substantially all of the study's clinical trial sites initiated by mid-2008. As a result, OXiGENE expects to reach the planned interim analysis by mid-2009."Investigators and trial site staff in the United States, Europe, Russia, and India are enthusiastic about participating in the ZYBRESTAT ATC study and are committed to undertaking this largest-ever clinical trial in anaplastic thyroid cancer," said OXiGENE's Chief Medical Officer, Patricia Walicke, M.D., Ph.D. About ZYBRESTAT (combretastatin A4 phosphate / CA4P) ZYBRESTAT(TM) is currently being evaluated in a pivotal registration study in anaplastic thyroid cancer (ATC) under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA). OXiGENE believes that ZYBRESTAT is poised to become the first therapeutic product in a novel class of small-molecule drug candidates called vascular disrupting agents (VDAs). Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical studies, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as clinical activity against ATC and other solid tumors. Additional information regarding the study design, enrollment criteria, and participating centers is available at http://www.clinicaltrials.gov (keyword: anaplastic thyroid cancer). About Anaplastic Thyroid Cancer ATC is one of the most aggressive cancers known in humans. There are no approved treatments for this disease. ATC is a high-grade neoplasm, characterized by a rapid clinical course with brief survival, and refractoriness to currently available local and systemic modalities of treatment. ATC comprises approximately two percent of all thyroid malignancies in the United States, and up to 5% in certain countries outside the United States. While ATC epidemiology has not been extensively studied and documented, OXiGENE estimates that there are approximately 1,000 to 4,000 new cases per year in the United States and in Europe combined. Newly-diagnosed ATC patients have a median life expectancy of approximately 3 months, and only a very limited number of patients survive for longer than one year. Information for Patients and Caregivers For further information about anaplastic thyroid cancer and the OXiGENE Phase II/III ZYBRESTAT(TM) clinical trial, please contact ThyCa: Thyroid Cancer Survivors' Association, Inc.: -0- *T ThyCA www.ThyCa.org (877) 588-7904 thyca@thyca.org *T About OXiGENE OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing VDAs that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and -enhancing medicines to patients. Safe Harbor Statement This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to: the timing of initiation of additional clinical trial sites for the Phase II/III trial of ZYBRESTAT for ATC; and the timing of the planned interim analysis of the Phase II/III trial results. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2006. OXiGENE, Inc. Investor Relations Shari Annes, 650-888-0902 sannes@oxigene.com
OXiGENE to Report on ZYBRESTAT(TM) Pivotal Trial Progress in Presentation to Investors in Sweden
| Source: Oxigene, Inc.